FAS Wealth Partners Inc. Sells 1,109 Shares of Pfizer Inc. (NYSE:PFE)

FAS Wealth Partners Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 4.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 25,687 shares of the biopharmaceutical company’s stock after selling 1,109 shares during the quarter. FAS Wealth Partners Inc.’s holdings in Pfizer were worth $681,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Eagle Strategies LLC grew its stake in shares of Pfizer by 30.5% during the 4th quarter. Eagle Strategies LLC now owns 12,212 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 2,852 shares during the period. Sulzberger Capital Advisors Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at about $312,000. Freestone Grove Partners LP bought a new stake in shares of Pfizer during the 4th quarter valued at about $481,000. Triumph Capital Management lifted its position in shares of Pfizer by 20.0% during the 4th quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 1,717 shares in the last quarter. Finally, Bridgewealth Advisory Group LLC lifted its position in shares of Pfizer by 31.3% during the 4th quarter. Bridgewealth Advisory Group LLC now owns 13,225 shares of the biopharmaceutical company’s stock valued at $339,000 after buying an additional 3,152 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $29.64.

Pfizer Stock Down 2.1 %

Shares of PFE opened at $23.91 on Friday. The stock has a market capitalization of $135.59 billion, a price-to-earnings ratio of 16.96, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The business’s 50 day simple moving average is $24.39 and its 200-day simple moving average is $25.82. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.82 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.19%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio is currently 124.64%.

Insider Activity

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.